Ting Xu

机构：The University of Texas MD Anderson Cancer Center, Dalian University, Shandong First Medical University, Chongqing Medical University · ORCID：0000-0002-7851-3389

发表论文 275 篇 · 总被引 5777 次 · h-index 39

代表论文

• Integrating ctDNA Analysis and Radiomics for Dynamic Risk Assessment in Localized Lung Cancer (2025 · Cancer Discovery · 被引 16)
• Efficacy and safety of biweekly single-dose actinomycin D versus multiday methotrexate in low-risk gestational trophoblastic neoplasia: a prospective multicenter randomized trial (2025 · Annals of Oncology · 被引 11)
• Bacteroides intestinalis mediates the sensitivity to irinotecan toxicity via tryptophan catabolites (2025 · Gut · 被引 10)
• JSKN003, a biparatopic anti-HER2 antibody drug conjugate (ADC), in the treatment of platinum-resistant ovarian cancer (PROC): Updated findings from two clinical trials. (2025 · Journal of Clinical Oncology · 被引 8)
• Toripalimab, bevacizumab, and irinotecan in dMMR/MSI locally advanced colorectal cancer: First-stage results from a phase 1b/2 trial (2025 · Cell Reports Medicine · 被引 7)
• Multiomic based Bayesian network toxicity modeling for simultaneous prediction of multiple toxicity outcomes in NSCLC (2025 · Radiotherapy and Oncology · 被引 6)